If indeed PP (a neuropeptide) activates somatostatin-containing cells in persons at risk for AD (e.g., APOE ε4 carriers), elevated levels of PP in APOE ε4 carriers may reduce excitatory signals, reduce the inhibitory–excitatory imbalance to GABAergic neurons, and promote memory encoding. This evidence concerns the gene SST and Alzheimer disease.